EU set to approve expansion of anti-Russia sanctions due to Siemens by August — sourceWorld July 28, 11:20
FSB detains Central Asians on suspicion of plotting terrorist attacks in St PetersburgWorld July 28, 11:16
At least 48 people injured in Barcelona train accidentWorld July 28, 10:17
Expert warns new sanctions against Russia may drive wedge between US and EUWorld July 28, 8:25
US Senate passes bill toughening anti-Russia sanctionsWorld July 28, 3:10
Launch of Sentinel-5p satellites scheduled for fallScience & Space July 28, 1:01
Russia, China round up joint naval exercise in Baltic SeaMilitary & Defense July 27, 21:27
Chechen leader says he is ready to quit his job to protect al-Aqsa Mosque in JerusalemSociety & Culture July 27, 21:07
Russian tennis star Sharapova granted wildcard for WTA tournament in CincinnatiSport July 27, 20:11
GENEVA, October 3. /TASS/. The Court of Arbitration for Sport (CAS) is set to announce a decision on the appeal of Russian tennis star Maria Sharapova, submitted in summer against her two-year ban, on Tuesday, October 4, the court said in its statement on Monday.
"Decision in the case of Maria Sharapova v. International Tennis Federation to be released at 3.00 pm (Swiss time) on 4 October 2016," the statement said.
On June 9, Sharapova filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed on June 8 by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
Due to the imposed ban world’s former No. 1 Sharapova had to miss the 2016 Summer Olympic Games, held in August in Brazil’s Rio de Janeiro.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.